Navigation Links
Dr. Michael A. Pfaller of T2 Biosystems to Discuss the Vital Role of Transformative Diagnostics in Optimizing Antimicrobial Stewardship in New Webinar
Date:1/11/2017

With sepsis claiming approximately 500,000 lives in the U.S. each year and costing healthcare systems more than $23.7 billion, healthcare systems are looking to provide better and faster care to their patients while controlling costs.

Among the most common sepsis-causing pathogens are bacteria and the yeast pathogen Candida, which can lead to severe complications and even death if not diagnosed and treated rapidly. Sepsis-causing pathogens are currently detected by blood culture which can take up to 6 days for results. However, T2 Biosystems’ first sepsis pathogen diagnostic panel, the T2Candida® Panel detects Candida independent of blood culture in an average of 4.3 hours which may enable physicians to quickly initiate appropriate therapy or discontinue unnecessary antimicrobial therapy.

Dr. Michael A. Pfaller is the Chief Medical Officer of T2 Biosystems and Professor Emeritus with the Departments of Pathology and Epidemiology at the University of Iowa, College of Medicine and College of Public Health. He will discuss how pairing a robust antimicrobial stewardship program with a rapid, highly sensitive, direct-from-blood diagnostic like the T2Candida Panel, can fundamentally change clinical decisions in a way that saves and improves the lives of patients while delivering a strong economic return to healthcare institutions.

Dr. Pfaller will discuss the preliminary details of the T2Bacteria™ Panel which is anticipated to complete clinical trials and be submitted to the FDA by mid-2017.

LabRoots will host the webinar January 31, 2017, beginning at 10:00 a.m. PT, 1:00 p.m. ET. To read more on this event, learn about the continuing education credits offered, or to register for this free event, click here.

About Dr. Michael A. Pfaller

Pfaller earned his medical degree from the Washington University School of Medicine. Pfaller currently serves as chief medical officer at T2 Biosystems, a role he’s held since 2014. He is a co-editor in chief of the 11th edition of ASM Manual of Clinical Microbiology and co-author of Medical Microbiology, 7th Edition and has authored over 700 articles in peer-reviewed journals.

About T2 Biosystems

T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit http://www.t2biosystems.com.

About LabRoots

LabRoots is the leading scientific social networking website and producer of educational virtual events and webinars. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.

Read the full story at http://www.prweb.com/releases/2017/01/prweb13966070.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
2. 2012-2013 Michael E. DeBakey Journalism Award Winners Announced
3. Validant Names Michael Beatrice as New Company President
4. Health Decisions CEO Michael Rosenberg Named a Business Leader Top Entrepreneur for 2013
5. Intra-Cellular Therapies Appoints Professor Sir Michael Rawlins to its Board of Directors
6. Envera Appoints Michael McErlean Fermentation Manager
7. Rhythm Awarded $1.35 Million from The Michael J. Fox Foundation to Advance Clinical Development of RM-131 for Refractory Constipation in Parkinsons Disease
8. Tor/Forge Launches THE CURE, a Riveting Thriller in the Tradition of Michael Crichton, by the New York Times Bestselling Author of WIRED.
9. First Annual Michael SanInocencio Lennox-Gastaut Syndrome Research Award Presented at Annual Meeting of the Child Neurology Society
10. 2013-2014 Michael E. DeBakey Journalism Awards Call for Entries - Viral Video
11. Business Guru Michael E. Gerber appointed to ReliantHeart Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2019)... ... October 02, 2019 , ... Murrieta Genomics , the launch ... venture capital companies in Silicon Valley at a special Life Science showcase event ... be held at the JJ Lake Business Center located at 340 E. Middlefield Road ...
(Date:9/24/2019)... , ... September 24, 2019 ... ... presenting their latest research in the area of high-level X-ray methods using ... Pamela Smith, COO of Improved Pharma, will present “Synchrotron X-Ray Diffraction and ...
(Date:9/24/2019)... ... September 24, 2019 , ... In the past three years, the National Science ... South Dakota School of Mines & Technology that expands human understanding of ... to form a slimy and yet strong layer which is commonly known as a ...
(Date:9/17/2019)... ... ... Jennifer Hermansky and Fang Xie, Ph.D. , attorneys from global ... Stars. Hermansky and Xie, named an Immigration Rising Star and a Life Sciences Rising ... The list highlights attorneys “whose legal accomplishments transcend their age,” according to Law360. , ...
Breaking Biology Technology:
(Date:9/30/2019)... ... September 30, 2019 , ... ... innovative human mesenchymal stem/stromal cell (hMSC) biomanufacturing systems, today announced it has ... (RTP) cellular product formats (patent number AU 2015259373). This new patent adds ...
(Date:9/25/2019)... ... September 25, 2019 , ... Modality ... ranked No. 3094 on Inc. Magazine’s annual Inc. 5000 list, the most prestigious ... of 120 percent. Based on this growth, the Houston-based firm also ranked No. ...
(Date:9/24/2019)... ... September 23, 2019 , ... Global molecular ... today that Holotype HLA and other Omixon products will be featured among 10 ... Society for Histocompatibility and Immunogenetics (ASHI) in Pittsburgh, PA. Omixon’s Lunch Symposium ...
Breaking Biology News(10 mins):